These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36504556)

  • 1. Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.
    Lee KN; Lee OY; Chun HJ; Kim JI; Kim SK; Lee SW; Park KS; Lee KL; Choi SC; Jang JY; Kim GH; Sung IK; Park MI; Kwon JG; Kim N; Kim JJ; Lee ST; Kim HS; Kim KB; Lee YC; Choi MG; Lee JS; Jung HY; Lee KJ; Kim JH; Chung H
    World J Gastroenterol; 2022 Nov; 28(44):6294-6309. PubMed ID: 36504556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
    Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
    Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
    Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
    World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.
    Schmitt C; Lightdale CJ; Hwang C; Hamelin B
    Dig Dis Sci; 2006 May; 51(5):844-50. PubMed ID: 16642422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
    Johnson DA; Benjamin SB; Vakil NB; Goldstein JL; Lamet M; Whipple J; Damico D; Hamelin B
    Am J Gastroenterol; 2001 Jan; 96(1):27-34. PubMed ID: 11197282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.
    Castell DO; Kahrilas PJ; Richter JE; Vakil NB; Johnson DA; Zuckerman S; Skammer W; Levine JG
    Am J Gastroenterol; 2002 Mar; 97(3):575-83. PubMed ID: 11922549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials.
    Gralnek IM; Dulai GS; Fennerty MB; Spiegel BM
    Clin Gastroenterol Hepatol; 2006 Dec; 4(12):1452-8. PubMed ID: 17162239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
    Raghunath AS; Green JR; Edwards SJ
    Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis.
    Lightdale CJ; Schmitt C; Hwang C; Hamelin B
    Dig Dis Sci; 2006 May; 51(5):852-7. PubMed ID: 16773434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
    Richter JE; Kahrilas PJ; Johanson J; Maton P; Breiter JR; Hwang C; Marino V; Hamelin B; Levine JG;
    Am J Gastroenterol; 2001 Mar; 96(3):656-65. PubMed ID: 11280530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
    Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
    J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of heartburn resolution and erosive esophagitis in patients with GERD.
    Orlando RC; Monyak JT; Silberg DG
    Curr Med Res Opin; 2009 Sep; 25(9):2091-102. PubMed ID: 19601705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.
    Fennerty MB; Johanson JF; Hwang C; Sostek M
    Aliment Pharmacol Ther; 2005 Feb; 21(4):455-63. PubMed ID: 15709997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety.
    Vakil NB; Shaker R; Johnson DA; Kovacs T; Baerg RD; Hwang C; D'Amico D; Hamelin B
    Aliment Pharmacol Ther; 2001 Jul; 15(7):927-35. PubMed ID: 11421866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
    Devault KR; Johanson JF; Johnson DA; Liu S; Sostek MB
    Clin Gastroenterol Hepatol; 2006 Jul; 4(7):852-9. PubMed ID: 16682260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and endoscopic evaluation of gastroesophageal reflux disease in patients successfully treated with esomeprazole.
    da Silva EP; Nader F; Quilici FA; Eisig JN; Zaterka S; Meneghelli U
    Arq Gastroenterol; 2003; 40(4):262-7. PubMed ID: 15264050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
    Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
    Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.